Royalty Report: Drugs, Biotechnology, Diagnostic – Collection: 4861


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 7


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7

Primary Industries

  • Drugs
  • Biotechnology
  • Diagnostic
  • Diagnostic Substances
  • Cancer
  • Disease
  • cardiac
  • Antibody
  • Assay

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4861

License Grant
The Licensee was granted the exclusive worldwide, right to a diagnostic assay useful for detecting lipoprotein (a), Lp; technical expertise to develop hybridoma cell lines that produce antibodies for use in such assay.
License Property
A lipoprotein is a biochemical assembly that contains both proteins and lipids, bound to the proteins, which allow fats to move through the water inside and outside cells.  Lipoproteins is any of a group of soluble proteins that combine with and transport fat or other lipids in the blood plasma.
Field of Use
The Licensee desires to grow such cell lines and harvest monoclonal antibodies from said cell lines and to make, use and sell products manufactured using such antibodies and desires to obtain the exclusive, worldwide rights to harvest such antibodies and make, use and sell such products.

IPSCIO Record ID: 2557

License Grant
The Licensee was granted exclusive, worldwide rights under the Licensed Patents and under the Licensed Technology to possess, use, make, have made, lease, sell and have sold all Materials, Progeny, Biomaterials, Technology, Improvements thereto, and Licensed Products.
License Property
Licensed Patents shall include U.S. Patent No. 5,484,735 to  Davis et al. filed November 12, 1993 and entitled Immunoassay of Glycosylated Proteins Employing Antibody to Reductive Glycosylated N-Terminal Amino Acids (hereinafter referred to as the 735 Patent).
Field of Use
Licensee desires to develop commercial diagnostic assays for determining hemoglobin in type Alc (Hb(Alc)) by detecting a reduced form of Hb(Alc).  Licensee desires to grow such cell lines and harvest monoclonal antibodies from said cell lines for the purpose of evaluating the suitability of the same for a commercial Hb(Alc) assay and for the purpose of evaluating whether to exercise an option to license the exclusive, worldwide rights associated with such cell lines, such monoclonal antibodies and such related information known to the Licensor.

IPSCIO Record ID: 27645

License Grant
Japanese Licensor grants to Licensee and its Affiliates the sole and exclusive, world-wide, royalty-bearing, assignable license under the Licensed Patents and Related Materials, with right to sublicense in one or more tiers of sublicenses, to research, develop, make, have made, use, sell, offer for sale, and import products and/or services in any and all fields of use or application.
License Property
Licensor owns certain rights in and to certain patents, information and materials related to the human antibody Pritumumab and a sister antibody to Pritumumab.

Licensed Patents
Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)
4,618,577 – human-human hybridoma, CLNH5

4,761,377 – human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells

5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins

5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas

5,286,647 – human-human hybridomas for neoplasms

5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.

5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.

6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions

6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies

6,051,693 – CLNH11-specific antibodies

6,090,924 – human-human CLNH5-specific antibodies

6,165,467 – stabilized human monoclonal antibody preparation

Field of Use
Pritumumab is a human monoclonal antibody[1] used in the treatment of brain cancer.

The goal of the Licensee is to become a leading oncology-focused biopharmaceutical company

IPSCIO Record ID: 6804

License Grant
The Licensor has a non-exclusive licensing Agreement with the Licensee for the use of hybridoma cell lines that are proprietary to the Licensor.
License Property
The cell lines generate monoclonal antibodies used in the Licensee's products.  

The Licensor provides vital products and services to facilitate the discovery, development and production of human and animal diagnostics and therapeutics. Their portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services.

IPSCIO Record ID: 1395

License Grant
Licensor hereby grants, and Licensee hereby accepts, the following licenses

(a) an exclusive, worldwide license, including the right to grant sublicenses, to develop, make, have made, import, use, sell, offer to sell or have sold Licensed Products and related cell lines, including the Sp2/0 Cell Line.

License Property
Licensor has developed a murine monoclonal antibody directed against the CCR5 antigen and designated by Licensee's as “PRO 140”

“Humanized Antibody(ies)” means the humanized form of the Murine Antibody.

“Licensed Product(s)” means products, for any use, incorporating substantially all of the Humanized Antibody or any modification, variant or fragment of the Humanized Antibody containing at least one variable region of the Humanized Antibody.

“Murine Antibody(ies)” means, subject to Section 2.01(b), the murine monoclonal antibody designated as “PRO 140” directed against the Target Antigen.

Field of Use
Licensee shall also evaluate the Humanized Antibody to determine whether such antibody also possesses anti-HIV activity not less than one-third (1/3) that of the Murine Antibody (“Minimum Anti-HIV Activity”) as measured according to an HIV-1 infectivity assay that measures the extent of HIV-l replication.

IPSCIO Record ID: 987

License Grant
The Company purchased certain equipment, inventory, cell lines and product rights for Macra-Registered Trademark- Lp(a).  In connection with this agreement, the Company agreed to pay Licensor a royalty on net sales of the Macra-Registered Trademark- Lp(a) product.
License Property
Macra Lp(a) is a microtiter plate assay that measures a lipoprotein found in human serum. This lipoprotein has been shown to be an indicator of risk for myocardial infarction, heart disease and stroke.

IPSCIO Record ID: 163133

License Grant
Licensor grants a Sublicense to Licensee and its Affiliates, to use the Licensor Antibodies, Cell Lines and Derivatives for the purpose of making, having made, using, selling and having sold Licensee Products.  Licensor shall provide Licensee quantities of Licensor Antibodies or Cell Lines and Derivatives, and information relating thereto.  Licensor agrees to deliver additional viable aliquots of Cell Lines or Derivatives to replace any aliquots previously delivered, which have subsequently become incapable of producing Licensor Monoclonal Antibodies and which are the same as the Licensor Cell Lines or Derivatives previously received by Licensee.

In order to protect Licensees source of supply of the Cell Lines or Derivatives Licensor warrants and agrees that Licensor shall maintain the Cell Lines and Derivatives in such a manner as will best preserve the viability thereof, in accordance with established scientific procedures.

License Property
Licensor holds exclusive licenses with respect to the Antibodies. Licensor is a supplier of specialty reagents, immuno-assay test kits and molecular research products to customers involved in biomedical research, the biotechnology industry and pharmaceutical drug discovery.

Monoclonal Antibodies to Human Interferongamma
        *1.       Antibody B133.5

         2.       Antibody 3C11C8

         3.       Antibody 2G1

Monoclonal Antibodies to Human Granulocyte Marophage-Colony Stimulating Factor

         1.       Antibody 3092

         2.       Antibody 3034

         3.       Antibody 1089

         4.       Antibody 4117

         5.       Antibody 2118

         6.       Antibody 1028

Monoclonal Antibodies to Human Tumor Necrosis Factor-alpha

         *1.      Antibody B154.7.1

         *2.      Antibody B154.9.1

Field of Use
The purpose for this agreement is for research use.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.